^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

    Excerpt:
    ...(Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)...
    Trial ID:
    NCT01423123
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

    Excerpt:
    ...(Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)...
    Trial ID:
    NCT01008150
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer

    Published date:
    11/17/2020
    Excerpt:
    The combination of N+T+F demonstrated encouraging clinical activity in heavily pre-treated HER2-mutant, HR+, HER2-non-amplified MBC, including patients who had previously received either fulvestrant and/or CDK4/6 inhibitor-based therapies...
    Secondary therapy:
    fulvestrant
    Trial ID:
    SUMMIT